

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Gastric cancer	Focal adhesion kinase (FAK); Src	<p>Cell culture studies suggest the <i>Enterolobium contortisiliquum</i>-derived trypsin inhibitor EcTI could help treat gastric cancer. In human gastric cancer cell lines, EcTI inhibited Src-FAK signaling and decreased migration and invasion compared with vehicle. Next steps include evaluating the cytotoxicity of EcTI.</p> <p>Sprycel dasatinib, a small molecule inhibitor of BCR-ABL tyrosine kinase and Src from Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. is marketed to treat acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML).</p> <p>Bosutinib, a dual inhibitor of BCR-ABL tyrosine kinase and Src kinase from Pfizer Inc., is under review for CML.</p> <p>At least five other companies have compounds targeting Src or FAK in Phase I trials or earlier to treat cancer.</p> <p>SciBX 4(45); doi:10.1038/scibx.2011.1264 Published online Nov. 17, 2011</p>	Patented; available for licensing	<p>de Paula, C.A.A. <i>et al. J. Biol. Chem.</i>; published online Oct. 28, 2011; doi:10.1074/jbc.M111.263996</p> <p>Contact: Maria Luiza V. Oliva, Federal University of Sao Paulo, Sao Paulo, Brazil</p> <p>e-mail: olivaml.bioq@epm.br</p>